MA27905A1 - Pyrazolines utilisees comme antagonistes par-1 pour traiter des maladies cardio-vasculaires - Google Patents

Pyrazolines utilisees comme antagonistes par-1 pour traiter des maladies cardio-vasculaires

Info

Publication number
MA27905A1
MA27905A1 MA28710A MA28710A MA27905A1 MA 27905 A1 MA27905 A1 MA 27905A1 MA 28710 A MA28710 A MA 28710A MA 28710 A MA28710 A MA 28710A MA 27905 A1 MA27905 A1 MA 27905A1
Authority
MA
Morocco
Prior art keywords
pyrazolines
treatment
cardiovascular diseases
par
antagonists
Prior art date
Application number
MA28710A
Other languages
English (en)
Inventor
Swen Allerheiligen
Dirk Brohm
Nicole Diedrichs
Britta-Nicole Frohlen
Christoph Gerdes
Mark Jean Gnoth
Heike Heckroth
Walter Hubsch
Elisabeth Perzborn
Elke Stahl
Verena Vohringer
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004010545A external-priority patent/DE102004010545A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MA27905A1 publication Critical patent/MA27905A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des pyrazolines de formule (I) dans laquelle E désigne méthylène, NH désigne un atome d'oxygène ou un atome de soufre, R2 désigne un groupe de formule (II). L'invention concerne également des procédé permettant de produire lesdites pyrazolines et leur utilisation pour préparer des médicaments utilisés dans le traitement et/ou la prophylaxie de pathologies, notamment de maladies cardio-vasculaires, comme par ex. des maladies thromboemboliques.
MA28710A 2003-07-15 2006-01-06 Pyrazolines utilisees comme antagonistes par-1 pour traiter des maladies cardio-vasculaires MA27905A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10331951 2003-07-15
DE102004010545A DE102004010545A1 (de) 2003-07-15 2004-03-04 Pyrazoline

Publications (1)

Publication Number Publication Date
MA27905A1 true MA27905A1 (fr) 2006-05-02

Family

ID=34081645

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28710A MA27905A1 (fr) 2003-07-15 2006-01-06 Pyrazolines utilisees comme antagonistes par-1 pour traiter des maladies cardio-vasculaires

Country Status (8)

Country Link
EP (1) EP1648447A1 (fr)
AU (1) AU2004257406A1 (fr)
BR (1) BRPI0412554A (fr)
CA (1) CA2532316A1 (fr)
MA (1) MA27905A1 (fr)
MX (1) MXPA06000507A (fr)
NO (1) NO20060733L (fr)
WO (1) WO2005007157A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004061748A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Azetidin-substituierte Pyrazoline
DE102004061751A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidin-substituierte Pyrazoline
DE102004061747A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Thiophen-substituierte Pyrazoline
CA2969771A1 (fr) * 2014-12-08 2016-06-16 Bayer Pharma Aktiengesellschaft Nouveaux composes d'aryl-cyanoguanidine
WO2016166186A1 (fr) 2015-04-17 2016-10-20 Bayer Pharma Aktiengesellschaft Nouveaux composés d'aryl-cyanoguanidine
US20180118722A1 (en) * 2015-04-17 2018-05-03 Bayer Pharma Aktiengesellschaft Novel aryl-cyanoguanidine compounds
EP3109237A1 (fr) 2015-06-22 2016-12-28 AnaMar AB Nouveaux antagonistes de 5-ht2
CN111892585A (zh) * 2020-08-05 2020-11-06 杭州维坦医药科技有限公司 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69131899T2 (de) * 1990-07-13 2000-08-17 Rohm & Haas N-Aryl-3-aryl-4-substituierte-4,5-dihydro-1H-pyrazol-1-carboxamide und Verfahren zu deren Herstellung
DE4217863A1 (de) * 1991-08-28 1993-03-04 Bayer Ag Substituierte pyrazoline
DE4217862A1 (de) * 1991-08-28 1993-03-04 Bayer Ag Substituierte pyrazoline
DE4217864A1 (de) * 1992-05-29 1993-12-02 Bayer Ag Substituierte Pyrazoline
DE4233713A1 (de) * 1992-10-07 1994-04-14 Bayer Ag Substituierte 4,5-Dihydro-1-pyrazolcarbonsäureanilide

Also Published As

Publication number Publication date
CA2532316A1 (fr) 2005-01-27
EP1648447A1 (fr) 2006-04-26
WO2005007157A1 (fr) 2005-01-27
MXPA06000507A (es) 2006-04-05
BRPI0412554A (pt) 2006-09-19
AU2004257406A1 (en) 2005-01-27
NO20060733L (no) 2006-04-10

Similar Documents

Publication Publication Date Title
MA27905A1 (fr) Pyrazolines utilisees comme antagonistes par-1 pour traiter des maladies cardio-vasculaires
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
MA27675A1 (fr) Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
MA30914B1 (fr) Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques.
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
MA29652B1 (fr) 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MA27933A1 (fr) Inhibiteurs de l'activite de akt
BRPI0410905A (pt) inibidores de p-38
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
TR200101709T2 (tr) İltihabik hastalıkların tedavisinde yararlı olan bileşikler
MA27668A1 (fr) 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
AP2001002088A0 (en) 4,4-Biarylpiperidine derivatives with opiod receptor activity.
MY138836A (en) Quinoline derivatives and their use as 5-ht6 receptor ligands
MA29672B1 (fr) [3.1.0] hétéroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type I
TNSN05238A1 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation pour le traitement de la douleur
TNSN07167A1 (fr) Indoles substitues, compositions les contenant, procede de fabrication et utilisation
TW200503710A (en) Novel compounds
MA27305A1 (fr) Derives de 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene et leur utilisation en tant qu'inhibiteurs de renine dans le traitement de l'hypertension, de maladies cardiovasculaires ou renales
GB0111186D0 (en) Novel compounds
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA28562B1 (fr) 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
ES2328496T3 (es) Compuestos de 1,4,8-triaza-espiro(4,5)decan-2-ona sustituidos.